Compare HSBC Holdings plc (HSBC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Zoetis Inc — how do they compare? HSBC Holdings plc trades at $103.05 (market cap $347.63B), while Zoetis Inc trades at $74.43 (market cap $31.59B). The key difference: HSBC Holdings plc is far larger — about 11× Zoetis Inc's market cap, and HSBC Holdings plc pays the higher dividend (3.71%). Which is the better fit depends on your goals.
| HSBC | ZTS | |
|---|---|---|
Market Cap | $347.63B | $31.59B |
Sector | Technology | Health |
52-Week High | $101.12 | $156.76 |
52-Week Low | $61.30 | $71.91 |
Dividend Yield | 3.71% | 2.81% |
Enterprise Value | — | $38.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $99.01, down 1.59% today but near its 52-week high of $99.47. The stock shows bullish technical momentum with strong moving average support and recent earnings beats in Q3 and Q4 2025. Revenue grew to $71.02B in 2025 with a healthy 30.81% net margin, though Q1 2026 missed expectations. Analyst sentiment is mixed with 38% buy ratings while the company executes strategic moves including AI partnerships and business portfolio optimization.
HSBC presents a balanced opportunity with solid profitability and strategic repositioning, but faces execution risks in its global restructuring. The current valuation at 16.37 P/E appears reasonable for a global bank, though regulatory challenges and market volatility require monitoring. Near-term catalysts include the upcoming Q2 earnings and continued progress on business simplification initiatives.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
